BioCentury
ARTICLE | Company News

Mylan, Pfizer genitourinary news

September 17, 2012 7:00 AM UTC

Pfizer and Mylan settled a June 2010 patent suit filed in the U.S. District Court for the District of New Jersey claiming that Mylan's ANDA for a generic version of Pfizer's overactive bladder (OAB) drug Detrol LA tolterodine infringed U.S. Patent Nos. 6,630,162 and 6,670,295 - formulation patents for the product. Under the settlement, Mylan may begin marketing its generic version as an authorized generic or under its own ANDA between Jan. 1, 2014, or earlier under undisclosed circumstances, and March 1, 2014, pending approval. The basic product patent for Detrol LA expires this month, while the formulation patents expire in December 2020. The companies declined to disclose details. ...